Ketamine or Etomidate for Tracheal Intubation of Critically Ill Adults [0.03%]
重症成人气管插管的氯胺酮与依托咪酯的效果比较研究
Jonathan D Casey,Kevin P Seitz,Brian E Driver et al.
Jonathan D Casey et al.
Background: For critically ill adults undergoing tracheal intubation, observational studies suggest that the use of etomidate to induce anesthesia may increase the risk of death. Whether the use of ketamine rather than et...
Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia [0.03%]
通用的基于CAR7的T细胞急性淋巴细胞白血病疗法
Robert Chiesa,Christos Georgiadis,Hebatalla Rashed et al.
Robert Chiesa et al.
Background: CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base-edited a...
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma [0.03%]
Teclistamab联合Daratumumab治疗复发或难治性多发性骨髓瘤
Luciano J Costa,Nizar J Bahlis,Aurore Perrot et al.
Luciano J Costa et al.
Background: In a phase 1-2 trial, teclistamab, a bispecific antibody targeting CD3 on T-cell surfaces and B-cell maturation antigen on myeloma cells, showed durable responses in heavily pretreated patients with relapsed o...
Adam Cuker,Thomas Stauch,Nichola Cooper et al.
Adam Cuker et al.
Background: Current second-line treatments for immune thrombocytopenia (ITP) require long-term administration. Ianalumab, a monoclonal antibody targeting B cells, is being assessed as a short-course second-line therapy in...
NEJM Clinician - Finding the Medicine That Matters in an Age of Infinite Evidence [0.03%]
《新英格兰医学期刊·临床医师版》——在证据无穷的时代寻觅有效的药物
Raja-Elie E Abdulnour,Eric J Rubin
Raja-Elie E Abdulnour
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia [0.03%]
固定疗程与连续治疗慢性淋巴细胞白血病的疗效比较
Othman Al-Sawaf,Janina Stumpf,Can Zhang et al.
Othman Al-Sawaf et al.
Background: Treatment of chronic lymphocytic leukemia (CLL) currently consists of two main approaches - continuous therapy with Bruton's tyrosine kinase inhibitors and fixed-duration regimens combining venetoclax with eit...
Ziad Obermeyer
Ziad Obermeyer
Prime Editing for p47phox-Deficient Chronic Granulomatous Disease [0.03%]
用于p47phox缺陷型慢性肉芽肿病的prime编辑疗法
Jennifer L Gori,Elie Haddad,Haydar Frangoul et al.
Jennifer L Gori et al.
Chronic granulomatous disease (CGD) is a severe monogenic immunodeficiency caused by damaging variants in genes required for microbicidal NADPH oxidase activity. Autosomal recessive p47phox-deficient CGD (p47-CGD) is predominantly caused by...
Enhancing FDA Drug-Safety Surveillance - Beyond Releasing Daily Adverse-Event Data [0.03%]
增强美国食品药品监督管理局的药物安全监察工作——每日不良事件报告数据发布之外
Joshua D Wallach,Joseph S Ross,Reshma Ramachandran
Joshua D Wallach
David S Jones,Scott H Podolsky,Justin Barr
David S Jones